Artax Biopharma Raises Series B Financing Extension
Artax Biopharma, Inc., a Cambridge, Mass.-based biotechnology company focused on transforming autoimmune disease treatment, completed an extension to its Series B financing led by Columbus Venture Partners.
Led by Joseph Lobacki, Chief Executive Officer, Artax Biopharma is a biotechnology company focused on autoimmune disease immunomodulation science, developing an innovative small molecule approach to treat autoimmune disease that modulates the immune system to both treat autoimmune disease and allow the body to fight foreign pathogens.
The company is examining a first-in-class oral immunomodulating agent as a new way to treat multiple autoimmune diseases without causing the immune suppression commonly associated with currently available autoimmune disease therapies.
AX-158 is an oral small molecule, immunomodulating agent in development for the treatment of autoimmune diseases.
It employs a novel mechanism of action that selectively modulates, or adjusts, T cell responses that play a critical role in immune system function.
Disclaimer: This story is auto-aggregated & summarized by a computer program and has not been created by StartupAround.
Two founders increase the odds of a startup’s success with 30% more investment, three times the customer growth rate, and a higher likelihood the startup will not scale too fast.
Search Startup Around
Boost Your Discovery with Us
Advertise with us to boost your article, content pience, product, event, conference discovery to our readers which includes founders, startup enablers, investors and every key stakeholders from global startup eco-system.